David Matly - Apr 1, 2025 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
President
Signature
/s/ Kelly Deck, as attorney-in-fact for David Matly
Stock symbol
INBX
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/2/2025, 04:34 PM
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBX Stock Option (right to buy) Award $0 +50K $0.00 50K Apr 1, 2025 Common Stock 50K $14.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on April 1, 2026, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.